What is BroadPharm?
BroadPharm is a leading biotechnology firm dedicated to the manufacturing and global distribution of high-purity chemical compounds essential for pharmaceutical research and development. Their extensive catalog features over 8,000 PEG linkers and 2,000 Click Chemistry reagents, alongside specialized components for antibody-drug conjugates (ADCs) and drug delivery lipids. The company also provides custom synthesis services and bioconjugation kits, aiming to accelerate R&D for clients worldwide through high-quality products and rapid delivery.
How much funding has BroadPharm raised?
BroadPharm has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for BroadPharm?
As BroadPharm navigates its large-scale, late-stage funding phase, the company is poised for significant growth and market penetration. The recent strategic investment suggests a focus on scaling operations, expanding its global reach, and potentially advancing its proprietary technologies. Future developments are likely to center on enhancing its bioconjugation capabilities and broadening its portfolio of specialized reagents to meet the evolving demands of the pharmaceutical and biotech industries. This strategic financing will be instrumental in solidifying BroadPharm's position as a key supplier in the drug discovery and development ecosystem.
See full BroadPharm company page
